// App-Quantinova.ai

1019 : A multi-marker prognostic to assess risk of invasive recurrence in DCIS patients.

Researchers

Presenter

  • Troy Bremer

Principal Investigators

  • Steven Paul Linke

  • Pat W. Whitworth

  • Rakesh Patel

  • Todd Barry

  • Stephen Lyle

  • Karl Simin

  • Karin Jirstrom

  • Fredrik Warnberg

Medical Centers

  • Prelude Corporation, Laguna Hills, CA

  • Prelude Corporation, Carlsbad, CA

  • NRG Oncology/NSABP, ALLIANCE/ACOSOG, and Nashville Breast Center, Nashville, TN

  • Western Radiation Oncology, Mountain View, CA

  • Spectrum Pathology, Mission Viejo, CA

  • University of Massachusetts Medical School, Worcester, MA

  • Department of Clinical Sciences, Lund University, Lund, Sweden

  • Regional Oncologic Centre, Uppsala University, Uppsala, Sweden

Locations

  • United States

  • Sweden

Companies

  • Prelude Corporation

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Cyclin Dependent Kinase Inhibitor 2A

  • Cyclooxygenase-2

  • erb-b2 receptor tyrosine kinase 2

  • Forkhead Box A1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved